Current challenges for the early detection of alzheimer's disease: Brain imaging and CSF studies

Journal of Clinical Neurology (Korea)

Volumn 5, Issue 4, 2009, Pages 153-166

  Mistur, Rachel ^a   Mosconi, Lisa ^a   de Santi, Susan ^a   Guzman, Marla ^a   Li, Yi ^a   Tsui, Wai ^a,b   de Leon, Mony J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Alzheimer disease; CSF markers; PET

Indexed keywords

EID: 77956183989     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2009.5.4.153     Document Type: Review

References (153)

1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56:1-120.
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol 1984; 34:939-944.
3. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122.
4. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurol 1991;41:479-486.
5. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
6. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogene-sis. Acta Neuropathol 1996;92:197-201.
7. Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurol 1999;52:1158-1165.
8. Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheiemer's disease. Neurology 1996;46:707-719.
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
10. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412-419.
11. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170.
12. Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman BT et al. Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. J Alzheimers Dis 1998;1:119-134.
13. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Mar-kesbery WR. Brain infarction and the clinical expression of Alzheimer's disease. The Nun Study. JAMA 1997;277:813-817.
14. Arriagada P V, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-1688.
15. Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuro-pathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol 1994;87:456-468.
16. Ulrich J. Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann Neurol 1985;17:273-277.
17. Selkoe DJ. Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997;275:630-631.
18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosa-tos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-6453.
19. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging. Neurobiol Aging 1998;19:109-116.
20. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004;10;Suppl:S34-S41.
21. de Leon MJ, McRae T, Tsai JR, George AE, Marcus DL, Freedman M, et al. Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy. Lancet 1988;2:391-392.
22. de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989;2:672-673.
23. Jack CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484-489.
24. Rusinek H, De Santi S, Frid D, Tsui W, Tarshish C, Convit A, et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 2003;229: 691-696.
25. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006;63:57-62.
26. O'Sullivan M, Ngo E, Viswanathan A, Jouvent E, Gschwendtner A, Saemann PG, et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol Aging 2009;30: 890-897.
27. Sokoloff L. Relation between physiological functions and energy metabolism in the central nervous system. J Neurochem 1977;29:13-26.
28. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 1999;283:496-497.
29. Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends Neurosci 2002;25:621-625.
30. Malonek D, Grinvald A. Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: implications for functional brain mapping. Science 1996;272:551-554.
31. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-st-ate brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003; 20:1894-1898.
32. Magistretti PJ, Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry 1996; 1:445-452.
33. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci US A 1994;91:10625-10629.
34. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486-510.
35. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorode-oxyglu-cose. J Comput Assist Tomogr 1983;7:590-598.
36. Frackowiak RS, Pozzilli C, Legg NJ, DuBoulay GH, Marshall J, Len-zi GL, et al. A prospective study of regional cerebral blood flow and oxygen utilization in dementia using positron emission tomography and oxygen-15. J Cereb Blood Flow Metab 1981;1:S453-S454.
37. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
38. Ferris SH, de Leon MJ, Wolf AP, Farkas T, Christman DR, Reisberg B, et al. Positron emission tomography in the study of aging and senile dementia. Neurobiol Aging 1980;1:127-131.
39. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005;128:1790-1801.
40. Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol 1984;16: 649-654.
41. Mazziotta JC, Phelps ME. Positron Emission Tomography studies of the brain. In: Phelps ME, Mazziotta JC, Schelbert H. Positron Emission Tomography & Autoradiography: Principles & Applications for the Brain & Heart. New York: Raven Press, 1986;493-579.
42. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17: 302-316.
43. Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286:2120-2127.
44. Szelies B, Mielke R, Herholz K, Heiss WD. Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogr Clin Neurophysiol 1994; 91:131-139.
45. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181-184.
46. Kennedy AM, Newman SK, Frackowiak RS, Cunningham VJ, Ro-ques P, Stevens J, et al. Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain 1995; 118:185-205.
47. Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186:17-20.
48. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006;47:1778-1786.
49. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-10971.
50. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, et al. Hip-pocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2008;29:676-692.
51. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impiarment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142.
52. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 2006;367:1262-1270.
53. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:494-504.
54. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12: 851-855.
55. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-539.
56. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometa-bolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343-351.
57. Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-1377.
58. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Will-och F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
59. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64:1860-1867.
60. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Si-ebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005;46:1625-1632.
61. Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging 2006;33:210-221.
62. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beu-thien-Beumann B, et al. Heterogeneity of brain glucose metaboism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728-1733.
63. Haxby JV, Grady CL, Koss E, Horwitz B, Heston L, Schapiro M, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990;47:753-760.
64. Reed BR, Jagust WJ, Seab JP, Ober BA. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurology 1989;39:1537-1539.
65. Berent S, Giordani B, Foster N, Minoshima S, Lajiness-O'Neill R, Koeppe R, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res 1999;33:7-16.
66. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-2340.
67. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
68. Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006;59:673-681.
69. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocri-nol Metab 2007;92:1023-1033.
70. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 Allele and the risk of Alzheimer's disease in late onset families. Science 1993;261: 921-923.
71. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
72. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in AP-OE transcription. J Neurochem 2003;84:1215-1236.
73. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Man-delkern MA, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947.
74. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334: 752-758.
75. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Book-heimer S, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-6042.
76. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E ep-silon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334-3339.
77. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004;101:284-289.
78. Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998;44:288-291.
79. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-So-banska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008;63:609-618.
80. Geerlings MI, Jonker C, Bouter LM, Adér HJ, Schmand B. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999; 156:531-537.
81. Bobinski M, de Leon MJ, Convit A, De Santi S, Wegiel J, Tarshish C Y, et al. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet 1999;353:38-40.
82. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med 2004;6: 192-196.
83. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002;287:329-336.
84. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 2005;62:565-573.
85. Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007;104: 19067-19072.
86. Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009;72:513-520.
87. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787-795.
88. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
89. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-1725.
90. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-1580.
91. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-2844.
92. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
93. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cere-brospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
94. Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2805-2807.
95. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Di-ehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuro-image 2008;39:619-633.
96. Mathis CA, Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004;10:1469-1492.
97. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007;130:2607-2615.
98. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001;21:RC189.
99. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-2663.
100. de Leon MJ, Mosconi L, Logan J. Seeing what Alzheimer saw. Nat Med 2007;13:129-131.
101. Powell MR, Smith GE, Knopman DS, Parisi JE, Boeve BF, Petersen RC, et al. Cognitive measures predict pathologic Alzheimer disease. Arch Neurol 2006;63:865-868.
102. Rowe CC, Ackermann U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neu-rol 2008;7:129-135.
103. Mitchell A, Brindle N. CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease? Int J Geriat Psychiatry 2003;18:407-411.
104. Brys M, Mosconi L, De Santi S, Rich KE, de Leon MJ. CSF biomarkers for mild cognitive impairment. J Aging Health 2006;2:111-121.
105. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
106. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet Neurology 2006;368:387-403.
107. Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000;166:201-203.
108. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Min-thon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
109. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009;30:682-690.
110. Büergernée Buch K, Padberg F, Nolde T, Teipel SJ, Stübner S, Ha-slinger A, et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neurosci Lett 1999;277:21-24.
111. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemen-schneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 1999; 52:1555-1562.
112. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vander-stichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
113. Glodzik-Sobanska L, Pirraglia E, Brys M, De Santi S, Mosconi L, Rich KE, et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 2009;30:672-681.
114. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997; 236:262-264.
115. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Stein-acker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimers disease. J Neural Transm 2005;112:933-948.
116. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001; 297:187-190.
117. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neu-rol 2002;59:1267-1272.
118. Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 2003;160:376-379.
119. Buerger K, Otto M, Teipel SJ, Zinkowski R, Blennow K, DeBernar-dis J, et al. Dissociation between CSF total tau and tau protein pho-sphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 2006;27:10-15.
120. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphory-lated at threonine 181 in human cerebrospinal fluid: a sandwich EL-ISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
121. Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wik-kelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:624-630.
122. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-94.
123. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001;22:77-78.
124. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401.
125. de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 2002;333:183-186.
126. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005; 107:165-173.
127. Tapiola T, Pirttilä T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, et al. Three-year follow-up of cerebrospinal fluid tau, B-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 2000; 280:119-122.
128. Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, et al. Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 2002;10:359-368.
129. Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Le-verenz J, et al. Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology 2002;59: 1139-1145.
130. Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 2001;57:1763-1766.
131. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006;63:936-939.
132. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
133. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagi-sawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000;43:155-160.
134. Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, et al. The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently. Neurobiol Aging 2001;22:209-215.
135. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neu-rol 1998;44:17-26.
136. Mehta PD, Pirttilä T, Mehta S P, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105.
137. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147.
138. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am J Pathol 1999;155:863-868.
139. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebro-spinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998;44:410-413.
140. Praticó D. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999;147:1-10.
141. Praticó D, Lawson JA, Rokach J, Fitzgerald GA. The isoprostanes in biology and medicine. Trends Endocrinol Metab 2001;12:243-247.
142. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neu-ropathol Exp Neurol 2001;60:759-767.
143. Praticó D, Uryu K, Leight S, Trojanowski JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001;21:4183-4187.
144. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxi-dation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005;58:730-735.
145. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999;52:562-565.
146. Praticó D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-812.
147. Praticó D, Clark CM, Liun F, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002;59:972-976.
148. de Leon MJ, Mosconi L, Li Y, De Santi S, Yao Y, Tsui WH, et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol 2007;254:1666-1675.
149. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VM, et al. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:475-478.
150. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005;57:721-729.
151. Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Qu-inn JF. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 2001;125:510-512.
152. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007;42:129-138.
153. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry 2002;159:738-745.